Our findings demonstrate that obesity leads to cardiac hypertrophy, as indicated by increased cardiac hypertrophy indices and altered biomarker levels. Changes in the RAF/MEK/ERK signaling pathway were closely associated with these outcomes, underscoring its central role in cardiac hypertrophy. Notably, eight weeks of treadmill EX mitigated cardiac hypertrophy indicators by modulating the RAF/MEK/ERK pathway.
Excessive carbohydrate intake, especially fructose and sugary beverages, contributes to increased obesity, LDL cholesterol, and triglyceride levels (
15). In a rat study, fructose-fed animals gained more weight than those fed sucrose after eight weeks (
16). High fructose diets promote fat accumulation and elevate blood triglycerides. Namekawa et al. reported that both high-fat and fructose-rich diets induce hyperlipidemia in rodents (
17). Thus, high-fat/high-fructose diets are widely used for inducing obesity in laboratory animals (
18).
Obesity or overweight status elevates the risk of cardiovascular diseases (
19). Increased left ventricular thickness, or cardiac hypertrophy, is a well-established marker of cardiac pathology resulting from excessive cardiac workload (
17). Cardiac hypertrophy involves enlarged myocytes due to overload. Addressing obesity is crucial for preventing early-onset cardiovascular disease; research shows a strong relationship between elevated Body Mass Index and cardiac hypertrophy as well as hypertension (
20-
22).
Previous research has shown that VEGF-B and SIRT3 are key regulators in the metabolism underlying cardiac hypertrophy; thus, targeting them may provide cardioprotection in heart failure (
23). In the present study, eight weeks of aerobic EX effectively reduced the risk of cardiac hypertrophy and improved VEGF-B and SIRT3 levels.
The current results also revealed significantly increased expression of RAF, MEK, and ERK genes in the cardiac tissue of OB rats relative to controls. Yu et al. demonstrated that modulating RAF expression improved hypertrophic cardiomyopathy, as evidenced by normalized end-diastolic lumen dimensions, cardiomyocyte morphology, and heart wall thickness (
24). Additionally, studies in children with Noonan syndrome and hypertrophic cardiomyopathy showed that off-label treatment with the oral MEK inhibitor trametinib resulted in improved cardiac function, reduced heart failure biomarkers, and favorable echocardiographic changes (
25).
The MAPK pathway, consisting of RAF, MEK, and ERK, is a major cascade activated by receptor tyrosine kinases (RTKs) upon ligand binding. Therapeutic modulation of this pathway presents an opportunity to treat cardiac hypertrophy (
26). Our findings are consistent with those of Mathieu et al. (
27), who observed an association between obesity and structural and functional cardiac alterations, as well as increased cardiovascular risk factors such as hypertension, dyslipidemia, and inflammation. Obesity exacerbates chronic inflammation, causing cellular damage and stress (
28), and activates the I kappa B kinase (IKK), nuclear factor kappa B (NF-kB), and MAPK pathways (
27). The MAPK family includes at least four pathways: The ERK1/2, ERK5, p38-MAPK, and c-Jun N-terminal kinases (JNK1/2/3) (
29). The MAPK/ERK pathway is implicated in numerous deleterious cellular processes (
30), and is activated via a phosphorylation cascade involving three protein kinases: The MAPK kinase, MEK, and MAPK. The MAPK/RAF-MEK-ERK complex is a developmental module involved in inflammatory and oxidative stress processes (
31). Matoba et al. demonstrated that elevated plasma free fatty acids increased cell proliferation and p70S6K phosphorylation by activating the MEK/ERK pathway in OB subjects (
32). Wang et al. reported that high-fat diets abnormally activate the MAPK pathway in adipocytes. Our results are in agreement, showing that an eight-week high-fat/high-fructose diet increases expression of MAPK downstream genes associated with cardiac hypertrophy indices and biomarkers (
33).
We observed significant suppression of RAF and MEK gene expression in OB rats subjected to EX, while ERK gene expression remained unchanged. This suggests that EX may primarily regulate the RAF/MEK/ERK pathway via transcriptional modulation of RAF and MEK. The ERK activity is often modulated post-translationally by phosphorylation rather than transcriptional changes, so unchanged ERK mRNA levels do not necessarily indicate unaltered pathway activity. Compensatory feedback mechanisms or selective targeting of upstream kinases by EX may maintain ERK transcript levels. These findings highlight the complex regulation of the MAPK pathway and the need for further research into ERK phosphorylation status to fully elucidate EX’s effects in obesity. Additionally, gene subfamilies (ERK1: MAPK3 and ERK2: MAPK1) may play roles, as full ERK activation requires phosphorylation at threonine 202 and tyrosine 204 (ERK1) or threonine 185 and tyrosine 187 (ERK2) (
31). Longer EX durations might influence ERK expression, warranting further study of isoform-specific roles in EX-induced MAPK modulation.
AMP-activated protein kinase (AMPK), a cellular energy sensor activated by EX, has been shown to inhibit the RAF/MEK/ERK pathway and reduce cardiac hypertrophy. This may partly explain the observed effects of aerobic EX. Pharmacological agents such as hydroxyurea, used in conditions like sickle cell disease, can also modulate MAPK signaling indirectly by altering nitric oxide and oxidative stress, highlighting the complexity of cardiac remodeling regulation (
34).
Aerobic EX significantly suppressed the RAF-MEK-ERK complex and decreased VEGF-B and SIRT3 concentrations, both biomarkers of cardiac hypertrophy. Further molecular research is needed to clarify the precise mechanisms by which aerobic EX prevents cardiac hypertrophy. Nonetheless, our results suggest that aerobic EX is a promising therapy for obesity-related cardiac disorders.
While our study demonstrates that aerobic EX impacts the RAF/MEK/ERK pathway in obesity-related cardiac hypertrophy, other signaling pathways, such as AMPK and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), may also be involved. AMPK, an energy sensor activated by EX, exerts antihypertrophic effects by reducing protein synthesis and controlling oxidative stress, and can inhibit MAPK signaling. Thus, reductions in cardiac hypertrophy may be indirectly mediated by AMPK activation. The PI3K/AKT pathway also plays a complex role in cardiac hypertrophy, with both physiological and pathological remodeling depending on upstream signals and activation duration. Interactions between the PI3K/AKT and MAPK pathways may contribute to hypertrophic signaling (
35). Therefore, the effect of aerobic EX on RAF and MEK expression may be partially mediated by these additional pathways. Future research should include protein-level analyses and pathway inhibition studies to further clarify these interactions.
The aerobic EX regimen — moderate-speed treadmill running for eight weeks — represents a moderate-intensity EX analogous to 3 - 6 metabolic equivalents (METs) in humans. According to established scaling models (
35,
36), this treadmill intensity in rodents is equivalent to brisk walking or light jogging in humans. This aligns with World Health Organization and American Heart Association recommendations for at least 150 minutes of moderate-intensity aerobic EX weekly to promote cardiovascular health. Thus, our results support the use of clinically relevant doses of aerobic EX to mitigate obesity-associated cardiac hypertrophy.
5.1. Conclusions
In summary, our findings indicate that aerobic EX can regulate cardiac hypertrophy in obesity by attenuating or modulating activation of the RAF/MEK/ERK pathway. This effect was clearly demonstrated in a high-fat/high-sugar diet model of obesity in male rats, suggesting a central role for this pathway in EX-induced cardiac hypertrophy responses. While our results are consistent with the literature, further studies are necessary to precisely define the underlying mechanisms and to clarify interactions between the RAF/MEK/ERK pathway and other cardiovascular signaling molecules and physiological parameters. Considering the study’s design, appropriate control groups, and use of an animal model, our results show that a high-fat/high-sugar diet and obesity can modify cardiovascular responses to aerobic EX. These findings have clinical implications for developing personalized EX programs for individuals with overweight or obesity to improve cardiac health, though clinical trials and longitudinal studies in humans are required to confirm applicability. Future studies should explore sex differences, combined dietary effects, and age-related responses to aerobic EX for optimal clinical intervention strategies.
5.2. Limitations
This study has several important limitations. First, the exclusive use of a male rat model limits generalizability to females; sex differences in cardiovascular and metabolic responses to obesity and EX may differentially affect the RAF/MEK/ERK signaling pathway. Second, translational relevance is constrained by species differences and controlled laboratory conditions (diet, housing, and activity) that do not replicate human lifestyle diversity. Third, reliance on a high-fat/high-sugar diet to induce obesity may not represent other obesity etiologies in humans, potentially limiting generalizability to non-diet-induced obesity. Fourth, while the mechanistic links to the RAF/MEK/ERK pathway are supported by the data, causality requires more targeted interventions (e.g., pathway-specific inhibitors or activators) to exclude off-target effects and confirm directionality. Fifth, study duration and EX protocol may influence results; longer-term or varied-intensity regimens might yield different cardiac remodeling insights. Sixth, potential confounders such as baseline metabolic status, physical activity, and circadian influences were not exhaustively controlled. Finally, while our findings align with existing research, replication in independent cohorts and alternative models is needed to strengthen the conclusions’ robustness and generalizability.